Studies of amiodarone treatment and anticoagulation in hypertrophic cardiomyopathy (HCM) patients
| Study | Therapy | No. of patients | Study design | Outcome |
|---|---|---|---|---|
| Robinson et al11 | A | 174 | 45 of 52 patients with AF received conventional therapy alone (25) or followed by amiodarone, 7 amiodarone only | Fewer alterations in drug therapy, fewer embolic episodes and more remained in SR, fewer direct current cardioversion attempts |
| Cecchi et al17 | A | 202 | 63 patients to manage NSVT, cardioversion or control or prevent AF or recurrence of cardiac arrest | No sudden death |
| Olivotto et al22 | A | 480 | 55.8% of patients with pAF | No difference of duration of SR and survival |
| Doi and Kitaoka13 | W | 91 | 45% of patients with AF anticoagulated | 42% of patients without warfarin vs 10% with warfarin experienced thromboembolism |
| Maron et al14 | W | 900 | 43.2% patients with AF anticoagulated | Cumulative incidence of thromboembolism among non-anticoagulated patients was twice that of patients anticoagulated (31% vs 18%) |
| Olivotto et al22 | W | 480 | 55.1% patients with AF anticoagulated | Stroke less common 10% vs non-treated 39% p<0.05 |
| Higashikawa16 | W | 83 | 37% (7 out of 19) of HCM patients with AF treated with warfarin | Ischaemic strokes in 6 out of 7 warfarin treated HCM patients with AF, INR<2 in 5 cases |
A, amiodarone; AF, atrial fibrillation; NSVT, non sustained ventricular tachycardia; pAF, paroxysmal atrial fibrillation; SR, sinus rhythm; W, warfarin.